Company / Total Assets
ALNYLAM PHARMACEUTICALS, INC. Total Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$5.0B
FY2025
5-year range
$3.5B / $5.0B
FY2021-FY2025
Trend
+17.1%
vs FY2024
Sector context
#27 of 214
Health Care
What the data says
ALNYLAM PHARMACEUTICALS, INC.'s total assets of $5.0B is higher than 87% of companies in the Health Care sector (FY2025). Total Assets has increased for 3 consecutive years, from $3.5B in FY2022 to $5.0B in FY2025.
Based on SEC 10-K filings.
$5.0B in FY2025 with a 5-year CAGR of +7.8%. Top quartile in the Health Care sector.
Improved from $3.8B to $5.0B over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- +11.9%
- 5-Year CAGR
- +7.8%
- 10-Year CAGR
- -
Sector benchmark
Top 13% in Health CareTop 13% of 214This company $5.0B Sector average $7.5B
▼
-33.5% below sector average
Key checks
Key Insights
- ALNYLAM PHARMACEUTICALS, INC.'s total assets has grown for 3 consecutive years.
- 5-year CAGR of +7.8%, indicating consistent growth.
- In FY2025, total assets increased 17.1% year-over-year.
- Ranks #27 out of 214 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.0B | +17.1% |
| FY2024 | $4.2B | +10.7% |
| FY2023 | $3.8B | +8.0% |
| FY2022 | $3.5B | -2.7% |
| FY2021 | $3.6B | +6.9% |
| FY2020 | $3.4B | +42.2% |
| FY2019 | $2.4B | +52.1% |
| FY2018 | $1.6B | -21.1% |
| FY2017 | $2.0B | +58.0% |
| FY2016 | $1.3B | -8.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026